Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CVKD · as of Sep 30, 2025
Ownership Breakdown
17
Institutional Holders
▲ 3 vs Q2
$1.57M
Total Inst. Value
▲ $750,396 vs Q2
2.87M
Shares Outstanding
freeFloat 79.72%
114,193
13F Shares Held
▲ 45,846 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CVKD largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 54.2K | 2.65% | 2.65% | $747.14M | Nov 7, 2025 | ▲ 5.6K |
CITADEL ADVISORS LLC pharmaceutical preparations | 19.9K | 97.18% | 97.18% | $273.63M | Nov 14, 2025 | NEW |
LPL FINANCIAL LLC pharmaceutical preparations | 14.2K | 69.47% | 69.47% | $196.39M | Nov 12, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 12.7K | 62.18% | 62.18% | $175.08M | Nov 12, 2025 | — held |
JPMORGAN CHASE & CO pharmaceutical preparations | 7.5K | 36.69% | 36.69% | $103.31M | Nov 26, 2025 | ▲ 7.5K |
BLACKROCK, INC. pharmaceutical preparations | 3.4K | 16.53% | 16.53% | $46.72M | Nov 12, 2025 | ▲ 96 |
MORGAN STANLEY pharmaceutical preparations | 880 | 4.31% | 4.31% | $12.17M | May 27, 2026 | ▲ 450 |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 500 | 2.45% | 2.45% | $6.48M | Nov 14, 2025 | — held |
ROCKEFELLER CAPITAL MANAGEMENT L.P. pharmaceutical preparations | 300 | 1.47% | 1.47% | $4.15M | Nov 14, 2025 | NEW |
JONES FINANCIAL COMPANIES LLLP pharmaceutical preparations | 172 | 0.84% | 0.84% | $2.41M | Nov 4, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
4
Increased
+13.7K shares4
New Positions
first time holders3
Decreased
−305 shares2
Sold Out
fully exitedNet shares change (top 50)
+13.4K
+13.7K / −305
Net new holders
+3
4 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CVKD insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
9
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Pham Quang X CEO and Chairman | Jun 3, 2026 | Sale | 2,323 | $4.26 | $9.9K | 179.2K | Form 4 ↗ |
Pham Quang X CEO and Chairman | Jun 4, 2026 | Sale | 3,898 | $4.41 | $17.2K | 175.3K | Form 4 ↗ |
Pham Quang X CEO and Chairman | Jun 5, 2026 | Sale | 2,064 | $4.42 | $9.1K | 173.2K | Form 4 ↗ |
Pham Quang X CEO and Chairman | May 29, 2026 | Sale | 303 | $5.01 | $1.5K | 181.9K | Form 4 ↗ |
Pham Quang X CEO and Chairman | Jun 2, 2026 | Sale | 349 | $4.46 | $1.6K | 181.5K | Form 4 ↗ |
Pham Quang X CEO and Chairman | May 11, 2026 | Sale | 6,476 | $5.76 | $37.3K | 188.4K | Form 4 ↗ |
Pham Quang X CEO and Chairman | May 12, 2026 | Sale | 3,298 | $5.28 | $17.4K | 185.2K | Form 4 ↗ |
Pham Quang X CEO and Chairman | May 28, 2026 | Sale | 2,989 | $4.93 | $14.7K | 182.2K | Form 4 ↗ |
Pham Quang X CEO and Chairman | May 22, 2026 | Sale | 1,165 | $5.69 | $6.6K | 194.9K | Form 4 ↗ |
Szot Matthew K Chief Financial Officer | Dec 29, 2025 | Sale | 9,933 | $6.97 | $69.2K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is primarily owned by institutional investors, who hold approximately 4.0% of total shares outstanding. Company insiders own approximately 20.28%, while retail and public investors account for the remaining 75.74%.
The largest institutional shareholder of Cadrenal Therapeutics, Inc. Common Stock is VANGUARD GROUP INC, holding approximately 54,239 shares — equal to 2.65% of outstanding shares — as of September 30, 2025.
A total of 17 institutional investors currently hold CVKD stock, with a combined institutional value of approximately $1,573,701 as of the most recent 13F filing period.
Frequently asked questions
CVKD ownershipCadrenal Therapeutics, Inc. Common Stock (CVKD) is primarily owned by institutional investors, who hold approximately 4.0% of shares. The largest shareholder is VANGUARD GROUP INC with a 2.65% stake. Company insiders hold 20.28%. Data sourced from SEC Form 13F as of September 30, 2025.